Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. regarding potential securities fraud or unlawful business practices. The investigation follows a June 24, 2026 press release in which ARS disclosed that its neffy epinephrine nasal spray had failed to secure commercial insurance coverage. On this news, ARS’s stock price fell $2.52 per share, or 23.91%, to close at $8.02 per share on June 25, 2026. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
ARS Pharmaceuticals, IncInvestigation for securities fraud and failure to secure insurance coverage for neffy, causing stock drop.